Greenwood pharmaceutical firm Elona Biotechnologies plans to build a $28 million production facility and create 70 jobs to
help develop a cheaper form of insulin that could gain significant market share.
The letter to Indianapolis-based Lilly cites a print advertisement for the antidepressant Cymbalta that did not adequately
display information about the drug’s side effects.
The agency said the meeting was canceled “to allow time for the FDA to review new information” about a proposed new use for
the drug.
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Pfizer Inc., the world’s largest drug maker, will pay a record $2.3 billion civil and criminal penalty over unlawful prescription
drug promotions, the Justice Department announced today.
A panel of five leaders of the state’s life sciences
industry took on a wide range of topics
July 24 at IBJ’s Power Breakfast
at the Westin Indianapolis.
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along the way.
Lilly executives want to make biotech their top focus.
Generic drug makers drive up the cost of name-brand drugs developed by locally based Eli Lilly and Co. and other pharmaceutical
firms.
Eli Lilly and Co. hopes to extend the life of its best-seller Zyprexa with a potentially lucrative, long-acting form of the antipsychotic drug. But first, the Indianapolis-based drugmaker must win over a panel of medical experts convened by the U.S. Food and Drug Administration on Feb. 6.
